122 related articles for article (PubMed ID: 28576169)
1. Urokinase Plasminogen Activator Receptor-PET with
Skovgaard D; Persson M; Kjaer A
PET Clin; 2017 Jul; 12(3):311-319. PubMed ID: 28576169
[TBL] [Abstract][Full Text] [Related]
2. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET.
Skovgaard D; Persson M; Kjaer A
PET Clin; 2017 Apr; 12(2):243-255. PubMed ID: 28267457
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
4. Safety, Dosimetry, and Tumor Detection Ability of
Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
[TBL] [Abstract][Full Text] [Related]
6. Prospective Phase II Trial of Prognostication by
Carlsen EA; Loft M; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2022 Sep; 63(9):1371-1377. PubMed ID: 35058319
[TBL] [Abstract][Full Text] [Related]
7. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
[TBL] [Abstract][Full Text] [Related]
8. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
9. Improved positron emission tomography imaging of glioblastoma cancer using novel
Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
[TBL] [Abstract][Full Text] [Related]
10.
Vats K; Sharma R; Sarma HD; Satpati D; Dash A
Anticancer Agents Med Chem; 2018; 18(9):1289-1294. PubMed ID: 29546835
[TBL] [Abstract][Full Text] [Related]
11. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [
Khare HA; Døssing KBV; Ringgaard L; Christensen E; Urbak L; Sillesen H; Ripa RS; Binderup T; Pedersen SF; Kjaer A
Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143
[TBL] [Abstract][Full Text] [Related]
12. Improved PET imaging of uPAR expression using new (64)Cu-labeled cross-bridged peptide ligands: comparative in vitro and in vivo studies.
Persson M; Hosseini M; Madsen J; Jørgensen TJ; Jensen KJ; Kjaer A; Ploug M
Theranostics; 2013; 3(9):618-32. PubMed ID: 24052804
[TBL] [Abstract][Full Text] [Related]
13. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
[TBL] [Abstract][Full Text] [Related]
14. First-in-human uPAR PET: Imaging of Cancer Aggressiveness.
Persson M; Skovgaard D; Brandt-Larsen M; Christensen C; Madsen J; Nielsen CH; Thurison T; Klausen TL; Holm S; Loft A; Berthelsen AK; Ploug M; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
Theranostics; 2015; 5(12):1303-16. PubMed ID: 26516369
[TBL] [Abstract][Full Text] [Related]
15. uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
Persson M; Juhl K; Rasmussen P; Brandt-Larsen M; Madsen J; Ploug M; Kjaer A
Mol Pharm; 2014 Aug; 11(8):2796-806. PubMed ID: 24955765
[TBL] [Abstract][Full Text] [Related]
16. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET.
Li ZB; Niu G; Wang H; He L; Yang L; Ploug M; Chen X
Clin Cancer Res; 2008 Aug; 14(15):4758-66. PubMed ID: 18676745
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of urokinase-type plasminogen activator receptor (uPAR) in prostate cancer: current status and future perspectives.
Skovgaard D; Persson M; Kjaer A
Clin Transl Imaging; 2016; 4(6):457-465. PubMed ID: 27933281
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.
Persson M; Kjaer A
Clin Physiol Funct Imaging; 2013 Sep; 33(5):329-37. PubMed ID: 23701192
[TBL] [Abstract][Full Text] [Related]
19. Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review.
Camedda R; Frantellizzi V; Danieli R; De Vincentis G; Filippi L
Expert Rev Anticancer Ther; 2024; 24(3-4):137-145. PubMed ID: 38451196
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial.
Fosbøl MØ; Kurbegovic S; Johannesen HH; Røder MA; Hansen AE; Mortensen J; Loft A; Petersen PM; Madsen J; Brasso K; Kjaer A
J Nucl Med; 2021 Mar; 62(3):354-359. PubMed ID: 32764119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]